Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device

Trial Information
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
Summary

This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate exacerbation and stable state asthma and COPD.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Minimum Age:
3
Healthy Volunteers:
No

• For COPD patients:

• Patients able and willing to sign an informed consent to participate in the study;

• Patient is aged 40 years or older with a smoking history of ≥10 pack years;

• Patients with COPD confirmed previously by a detailed medical history and examination;

• Patients presenting with moderate or severe exacerbation of chronic obstructive pulmonary disease.

• Patient is treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS.

• For asthma patients:

• Patients able and willing to sign an informed consent to participate in the study;

• Patient is aged 3 years or older;

• Patients with asthma confirmed previously by a detailed medical history and examination;

• Patients presenting with moderate or severe exacerbation of asthma;

• Patient is treated by a monotherapy ICS or ICS plus LABA or other controllers.

Where is this trial taking place?
Other Locations
Belarus
Minsk Clinical Phthisiopulmonology Center
Recruiting
Minsk
Who do I contact about this trial?
Primary
Helena Binetskaya
helena@lungpass.com
+375333130806
Backup
Olga Kharevich, MD, PhD
o_harevich@tut.by
+375298649803
When is this trial taking place?
Start Date: September 30, 2021
Estimated Completion Date: September 30, 2022
How many participants will be in this trial?
Target number of participants: 200
What treatment is being studied in this trial?
Asthma
Asthma patients aged 3 years and older with confirmed asthma diagnosis treated by a monotherapy ICS or ICS plus LABA or other controllers and presenting with moderate or severe disease exacerbation
COPD
COPD patients aged 40 years and older with confirmed COPD diagnosis treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS and presenting with moderate or severe disease exacerbation
Who are the authors of this trial?
Elena Loban

This content was sourced from clinicaltrials.gov